发起交叉创新邀请
生物科学领域
深圳合成生物学创新研究院
Shenzhen Institute of Synthetic Biology
国家
中国
地点
深圳
依托单位
深圳先进技术研究院
主体类型
科研性质
涉及学科
理学
涉及领域
生物科学
研究方向
定量合成生物学;合成基因组学;合成生物化学;合成微生物组学;材料合成生物学;合成免疫学
主体简介

深圳合成生物学创新研究院(以下简称“深圳合成院”)是由中国科学院深圳先进技术研究院牵头建设的非法人科研机构,核心参与单位是深圳市第二人民医院和深圳华大生命科学研究院,2019年1月,由合成所(中国科学院深圳先进技术研究院第七个研究所)以“院所共建”的形式具体建设。深圳合成院秉承“造物致知,造物致用”的建院理念,以建成构建生命,理解生命,融合BT和IT的世界一流合成生物学研究机构为愿景,聚焦人工生命体系的理解,致力于重塑与扩展这一重大科学挑战,开展合成生物学基本原理、共性方法和医学转化应用研究。依托合成所在人才、科研及产业的多年积累,在国家部委、中科院及地方政府的支持下,深圳合成生物学创新研究院已初步建成“五位一体”、多主体合作、多要素联动的综合创新生态模式。
(1)研究:2017年12月,深圳先进技术研究院成立国内首个合成生物学研究所。目前已形成以青年“海归”为主,全球聚焦合成生物学领域最大规模的前沿多学科交叉团队。2018年11月,深圳批复建设深圳合成生物学创新研究院,院所一体化建设(深圳市政府5年投资7.5亿元,深圳十大基础研究机构之一)。
(2)平台:深圳正在率先建设全球最大的合成生物研究重大科技基础设施,主体建筑已于2021年1月封顶。该设施将建成先进的智能化生命系统设计与制造平台,为全国合成生物学研究提供强有力的支撑。(深圳市政府投资7.22亿元,不含基建费用)
(3)教育:2019年10月,中国科学院深圳理工大学正式获批纳入广东省高校设置“十三五”规划,开始筹建。其中,合成生物学学院为拟设立的六大学院之一,这将进一步提升合成生物学领域的原始创新能力,并为该领域持续提供高质量青年人才。
(4)产业:2020年4月,深圳市工程生物产业创新中心落户光明科学城,打造国内首个“楼上楼下创新创业综合体”,将打破研究院应用研究与初创企业的空间距离,有效解决初创企业缺乏设施和技术平台的瓶颈,极大缩短原始创新到产业转化的时间周期(深圳市政府投资9216万元)。
(5)资本:结合合成生物学学科及产业发展现状,集聚国内外科研人才与优秀投资管理人才,发起成立“星博生辉”合成生物产业基金,为合成生物学初创企业提供适宜土壤,进一步保障与推进合成生物学产业健康高速发展。
深圳合成生物学创新研究院作为深圳自主建设的高水平科研平台,将紧紧围绕建设粤港澳大湾区国际科技创新中心的目标,按照国际一流标准开展科学研发。深圳合成院将提升深圳合成生物学领域科技创新水平和自主创新能力,重点补齐合成生物学基础研究短板,攻坚克难,不断践行和探索 “基础研究+技术攻关+成果产业化+科技金融”全过程创新生态链,为全力打造可持续发展的全球创新创意之都不懈努力。

Shenzhen Institute of Synthetic Biology innovation (HEREINAFTER referred to as "SHENZHEN Institute of Synthetic Biology") is an unincorporated scientific research institution led by Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. The core participating units are Shenzhen Second People's Hospital and Shenzhen Huada Institute of Life Sciences. It will be built by the Institute of Synthesis (the seventh institute of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences) in the form of "institute co-construction". Shenzhen synthetic hospital adhering to the "practical knowledge creation, creation" built courtyard concept, built to build a life, understand life, fusion of BT and IT world class synthetic biology research institution for vision, focused on the understanding of the system of artificial life, committed to restore and expand the great scientific challenges, to carry out the basic principle of synthetic biology, common methods and the transformation and application of medical research. With the support of national ministries and commissions, Chinese Academy of Sciences and local governments, SHENZHEN Institute of Synthetic Biology Innovation has preliminarily established a "five-in-one", multi-agent cooperation and multi-factor linkage comprehensive innovation ecological mode.
(1) Research: In December 2017, SHENZHEN Institute of Advanced Technology established the first synthetic biology institute in China. At present, it has formed the largest cutting-edge multidisciplinary team focusing on the field of synthetic biology, mainly composed of young "overseas returnees". In November 2018, Shenzhen approved the establishment of Shenzhen Institute of Synthetic Biology Innovation, which is one of the top ten basic research institutes in Shenzhen with a 5-year investment of 750 million YUAN from shenzhen Municipal Government.
(2) Platform: Shenzhen is taking the lead in building the world's largest major scientific and technological infrastructure for synthetic biology research, and the main building has been capped in January 2021. The facility will be built into an advanced intelligent life system design and manufacturing platform, providing strong support for synthetic biology research across the country. (Shenzhen Municipal Government invested 722 million yuan, excluding infrastructure costs)
(3) Education: In October 2019, Shenzhen University of Technology, Chinese Academy of Sciences (CAS) was approved to be included in the "13th Five-Year Plan" of colleges and universities in Guangdong Province, and began its preparation. Among them, the School of Synthetic Biology is one of the six schools to be established, which will further enhance the original innovation capacity of synthetic biology and provide high-quality young talents for the field.
(4) Industry: In April 2020, Shenzhen Engineering Biological Industry Innovation Center will be settled in Guangming Science City, creating the first "upstairs and downstairs innovation and entrepreneurship complex" in China, which will break the space distance between applied research institutes and start-ups and effectively solve the bottleneck of start-ups lacking facilities and technology platforms. Greatly shorten the time cycle from original innovation to industrial transformation (Shenzhen Municipal government invested 92.16 million yuan).
(5) Capital: Based on the development status of the discipline and industry of synthetic biology, we will gather domestic and foreign scientific research talents and excellent investment management talents to launch the establishment of "Singbo Shenghui" Synthetic Biology Industry Fund to provide suitable soil for synthetic biology start-ups and further guarantee and promote the healthy and rapid development of the synthetic biology industry.
As a high-level scientific research platform independently built by Shenzhen, SHENZHEN Institute of Synthetic Biology Innovation will closely focus on the goal of building an international science and technology innovation center in the Guangdong-Hong Kong-Macao Greater Bay Area, and carry out scientific research and development in accordance with international first-class standards. Synthetic biology will raise of the shenzhen synthetic shenzhen science and technology innovation level and the capacity for independent innovation, focus on completion of synthetic biology basic research, overcome difficult, constant practice and explore "basic research + technology + + financial science and technology industrialization of achievement of" the whole process of innovation ecosystem, as a global innovation ideas of sustainable development of make unremitting efforts.

联系方式
isynbiopr@siat.ac.cn
  • 理学前沿案例
  • 理学前沿热点
  • 生物育种科学创新思维 | 利用分子遗传技术和花粉特异性酶研究植物花粉生产生长素和淀粉
  • PRC2蛋白质调节决定胚胎发育的最初细胞
  • STAND atp酶蛋白通过识别病毒三维结构对抗病毒感染
  • 通过追踪鞘脂新技术发现母乳喂养对婴儿肠道微生物群的影响
  • 创新利用TadA8e进入双链DNA进行碱基转换
  • 发育生物学创新思维 | 鼻孔起源的物理原理创新研究
  • 生命科学理论创新 | 通过研究“fusogens”蛋白推测细胞受精过程起源于30亿年前
  • 生物科学创新思维 | 创新免疫疗法对抗乙型肝炎病毒
  • 细胞学创新 | 细胞在粘液中的移动速度机制创新研究
  • 生物科学创新思维 | PABP/R-motif介导的蛋白重编程新机制
    相关创新主体
    • 麻省理工学院-环境健康科学中心
    • 马克斯·普朗克生物物理研究所
    • 芝加哥大学生物物理动力学研究所(IBD)
    • 中国科学院水生生物研究所
    • 欧洲分子生物学实验室
    • 中国科学院动物研究所
    • 斯坦福大学肖恩·n·帕克过敏和哮喘研究中心
    • 中国科学院武汉病毒研究所
    • 法国国家科学研究中心生物科学研究所(INSB)
    • 中国科学院成都生物研究所
    • 魏茨曼科学研究所
    • 马克斯·普朗克分子细胞生物学与遗传学研究所
    • 英国国家计量研究所
    • 九州大学实验生物环境控制中心
    • 首尔国立大学格林生物科学技术研究所
    • 中国科学院微生物研究所
    • 芝加哥大学综合生理学研究所(IIB)
    • 中国科学院生物物理研究所
    • 马克斯·普朗克衰老生物学研究所
    • 伦敦大学学院生物科学部